Active, not recruitingPhase 3NCT06724809
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
Studying Neuromyelitis Optica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Principal Investigator
- Xiangjun Chen, M.DHuashan Hospital
- Intervention
- eculizumab(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 18-130 years · All sexes
- Timeline
- 2025 – 2026
Study locations (7)
- Research Site, Beijing, China
- Research Site, Dongguan, China
- Research Site, Jinan, China
- Research Site, Shanghai, China
- Research Site, Taiyuan, China
- Research Site, Wenzhou, China
- Research Site, Wuhan, China
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06724809 on ClinicalTrials.govOther trials for Neuromyelitis Optica
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyAmgen
- RECRUITINGPHASE3NCT05199688A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Hoffmann-La Roche
- RECRUITINGPHASE4NCT07420296Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderTianjin Medical University General Hospital
- RECRUITINGNCT06885957Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDTongji Hospital
- RECRUITINGPHASE1NCT06620809The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersTongji Hospital
- RECRUITINGNANCT06865274Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT06780709Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSDIcahn School of Medicine at Mount Sinai
- ENROLLING BY INVITATIONNANCT06374264Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum DisorderMedRhythms, Inc.